Amerisource
AmerisourceBergen Corporation, commonly referred to as Amerisource, is a leading global healthcare solutions provider headquartered in the United States. Founded in 2001, the company has established itself as a key player in the pharmaceutical distribution industry, serving healthcare providers across North America and beyond. Amerisource focuses on the distribution of pharmaceutical products, including specialty drugs and biologics, while also offering innovative services that enhance patient care. Its commitment to improving healthcare delivery is evident through its unique approach to supply chain management and patient support services. With a strong market position, Amerisource has achieved notable milestones, including strategic partnerships and acquisitions that have expanded its operational reach. The company continues to be recognised for its dedication to quality and efficiency in the healthcare sector.
DitchCarbon Score
How does Amerisource's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Maritime Transport industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amerisource's score of 5 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amerisource's reported carbon emissions
In 2020, Amerisource reported total carbon emissions of approximately 111,000,000 kg CO2e, comprising 33,361,300 kg CO2e from Scope 1, 74,293,600 kg CO2e from Scope 2, and 25,777,700 kg CO2e from Scope 3 emissions related to business travel. This reflects a slight decrease in Scope 1 emissions from 2019, which were about 33,597,500 kg CO2e, while Scope 2 emissions decreased from approximately 86,713,900 kg CO2e, and Scope 3 emissions from business travel decreased from about 28,356,600 kg CO2e. Amerisource has set ambitious climate commitments, aiming for net zero emissions by 2050 for both Scope 1 and Scope 2 emissions. These long-term targets were established in 2023, demonstrating the company's commitment to reducing its carbon footprint and addressing climate change. The company has not disclosed specific targets under the Science Based Targets initiative (SBTi) but is actively working towards its net zero goal. Overall, Amerisource's emissions data and climate commitments reflect a proactive approach to sustainability within the pharmaceutical distribution industry, aligning with global efforts to mitigate climate change impacts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | |
|---|---|---|
| Scope 1 | 33,597,500 | 00,000,000 |
| Scope 2 | 86,713,900 | 00,000,000 |
| Scope 3 | 28,356,600 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amerisource is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
